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Mesenchymal stem cells (MSCs) are in development for many clinical indications, based both on ‘stem’
properties (tissue repair or regeneration) and on signaling repertoire (immunomodulatory and anti-
inlammatory effects). Potential conlation of MSC properties with those of tissue-derived stromal cells
presents dificulties in comparing study outcomes and represents a source of confusion in cell therapy
development. Cultured MSCs demonstrate signiicant heterogeneity in clonogenicity and multi-lineage
differentiation potential. However in vivo biology of MSCs includes native functions unrelated to regen-
erative medicine applications, so do nomenclature and heterogeneity matter? In this perspective we ex-
amine some consequences of the nomenclature debate and heterogeneity of MSCs. Regulatory expecta-
tions are considered, emphasizing that product development should prioritize detailed characterization
of therapeutic cell populations for speciic indications.
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Variation is a fundamental concept in biology. While conservation of genes over evolutionary time spans allows for
the preservation of essential processes common to all life it is variation that enables adaptation and survival. Within
species, biological and behavioral traits exhibit a continuous spectrum of variation [1] which are likely to be based
in part on variations in gene expression [2]. Even highly conserved RNA genes exhibit both species differences and
variations in expression across different tissues [3].
Within a clonal population of cells, variations in gene expression between individual cells arise due to both
extrinsic and intrinsic factors which determine the exact profile of gene expression and biological activities [4]. Since
changes in signaling activity will impact upon the environment of other cells in the population, heterogeneity is
inevitable even when the cells are genetically identical. Heterogeneity in cell communities may in fact be critical
to many biological processes [5], but is generally not considered in the routine characterization of cell populations,
where properties are frequently reported on an averaged basis. Although variation is inevitable, limitations in our
ability to detect and control heterogeneity brings with it challenges for the production of cell therapies in which
cells are the active substance in a medicinal product. Increasingly sophisticated techniques allow elucidation of
expression profiles at the single cell level [6] which may provide insights useful for the optimization of cell culture
for regenerative medicine products. Since one of the goals of medicinal product manufacture is consistency, can we
reconcile variation at the individual cell level, for example as detected in RNA sequencing [7] or microfluidics [8],
with the population-based measurements currently used to characterize cells for regenerative medicine? How closely
should we seek to control cell phenotype and expression profile to achieve a therapeutic goal? Are there benefits of
population heterogeneity for the therapeutic effects of the product?
The regulatory frameworks for medicinal products, which includes cell therapies, require developers to define
and produce consistently a specific product which is controlled in terms of its quality attributes. Developers need
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Figure 1. EU clinical trials involving ‘mesenchymal stem cell’.
A total of 27 (28%) of the 98 mesenchymal stem cell clinical trials currently registered on EudraCT involve
immunomodulatory properties of mesenchymal stem cell. A total of 22 (22%) are skeletal applications (bone, tendon
repair, osteoarthritis), 15 (15%) address wound healing applications (skin ulcers, burns, istulae). Cardiovascular (eight
trials, 8%) and CNS (six trials, 6%) indications cover the majority of other trials.
Source: EudraCT www.clinicaltrialsregister.eu (Accessed 3 November 2018).
to consider how to achieve routine manufacture of safe and efficacious cell therapies when the very nature of the
starting material seems to undermine this objective.
Mesenchymal stem/stromal cells (MSCs) represent a significant fraction of the current efforts to develop cell-
based treatments for a range of diseases. There are at present 98 clinical trials involving mesenchymal stem/stromal
cells as the investigational medicinal product registered with the European clinical trials database EudraCT (Fig-
ure 1). The colony-forming fibroblastic adherent cell population originally described by Friedenstein et al. [9] have
become the cell of choice for many regenerative medicine applications, and the literature expands daily.
In this perspective we consider the impact of biological heterogeneity on some of the regulatory requirements
to which MSC-based therapies are subject, and discuss how these factors might impact upon the use of MSC in
regenerative medicine.
MSC nomenclature
One of the most challenging aspects of MSCs is the perennial debate over nomenclature: ‘stem’ versus ‘stromal’ and
thus identity. Stem cells may be defined by two broad properties: the capacity for self-renewal and symmetric and
asymmetric division, through which they produce lineage-committed progenitors which ultimately differentiate
into tissue-specific cells [10]. Stem cell homing in response to specific cues results in formation of new functional
tissue in vivo [11].
The term ‘mesenchymal stem cell’ originated with Caplan [12] following success in generating cartilage and bone
tissue from ex vivo culture of embryonic chick mesenchymal tissue. Similar findings were obtained using cultured
cells derived from the periosteum; the author did not examine other tissues but contended that a similar approach
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Table 1. International Society for Cell and Gene Therapy criteria for identiication of multipotent mesenchymal stromal
cells.
Characteristic Requirement
Plastic adherence Adherent
Surface antigens CD73, CD105, CD90
CD34, CD45, CD14 or CD11b, CD79 or CD19, HLA-DR
≥95% positive
≤2% positive
Differentiation potential in vitro to: Osteocytes
Chondrocytes
Adipocytes
would be suitable to assess other mesenchymal tissues. This paper was one of the first to suggest the potential for
use of ex vivo culture-expanded cells to produce replacement skeletal tissues as a therapy.
The literature abounds with descriptions apparently conflating bone marrow-derived stem cells, which combine
demonstrated self-renewal with intrinsic skeletogenic differentiation potential, with stromal cells from a range of
different tissue sources, both structural and nonstructural. A multiplicity of terms, each with its own implicit
assumptions, has arisen, and despite repeated calls for clarity rooted in the specific biology of the cells, notably from
the International Society for Cell and Gene Therapy (ISCT) [13] and others [14–17], many reports contribute to the
confusion by failing to distinguish between true stem cells residing in the bone marrow and a variety of clonogenic
stromal populations with varied characteristics.
The ISCT recommended a clear distinction between the bone marrow-derived self-renewing fraction with proven
multi-potent differentiation in vivo (mesenchymal stem cells) and mesenchymal stromal cells from multiple tissues,
shown to be multi-potent via in vitro differentiation assays [13]. Since the acronym ’MSC’ was already embedded
in the literature, the ISCT did not recommend a new term but rather emphasized the importance of definition of
stem or stromal cell within studies. The use of the ‘MSC’ acronym is even more widely used now than in 2005,
thus there is no attempt to redefine terms here, but rather to reiterate the need for meaningful descriptions of cell
populations based on properties rather than expectations.
‘MSCs’ are described in the literature in broadly two ways: firstly specifically the rare cellular component of
bone marrow, proven to be self-renewing, clonogenic and capable of producing skeletal tissues only, via in vivo
serial transplantation [16,18]. This approach to derivation and characterization followed the paradigm used for
hematopoietic stem cells, in which individual clonal populations have been evaluated by serial transplantation
into recipient animals, thereby demonstrating both self-renewal and multipotency. Alternatively MSC are stromal
progenitors found in multiple tissue types, which can be induced to differentiate in vitro into different lineages
beyond skeletal tissues [19,20]. Much of this literature has to a large extent used a panel of surface markers, individually
not necessarily specific for MSCs, and properties such as those proposed by the ISCT position statement [21] (Table 1)
to characterise a wide range of cells from many different tissue sources.
The ISCT criteria were intended to address the increasing difficulties in comparing outcomes from studies
with cells isolated from different tissues and via different culture protocols. Although the authors stated that they
were not intended to serve as release criteria for clinical applications, the ISCT criteria have become a de facto
‘standard’ for MSCs: many research papers, and also clinical trial applications [22] appear to rely on these criteria as
being sufficient to characterise the population under investigation. However none of the parameters are specific to
MSCs [23,24]. Although widely used in primary research and as a tool to confirm multipotentiality, the standard in
vitro differentiation assays have been criticized for their lack of specificity and robustness [17].
A further use of the MSC acronym has been proposed, this time for Medicinal Signaling Cell [25–27] based on
cells’ expression of trophic and immunomodulatory factors rather than differentiation capacity. Abandonment of
the general MSC term and replacement with tissue-specific stromal cell descriptors has been recommended [17].
MSCs in vivo
The existence of a nonhematopoietic stem cell within bone marrow was confirmed via a number of key studies, sum-
marized by Bianco [18]: in vivo transplantation of increasingly well-defined elements of the bone marrow showed that
transplanted fragments of whole bone marrow induced formation of bone and hematopoietic microenvironment
in heterotopic organoids. Transplantation of clonally derived populations located skeletal potential in individual
progenitor cells. Eventually serial transplantation of individual putative bone marrow stem cells demonstrated that
CD146 identifies an in vivo population (sub-endothelial adventitial reticular cells [ARC] in the walls of bone mar-
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row sinusoids) and that selection by CD146 expression isolates a population including clonogenic, self-renewing
multi-potent cells capable of forming both bone and hematopoiesis-supporting stroma upon transplantation.
MSCs are an integral component of the hematopoietic niche in bone marrow [28,29]. The composition of this
niche and the role of MSCs within it has been investigated extensively over the last 10 years, with progress
reviewed in, Hanoun and Frenette [30], Morrison and Scadden [31], Asada et al. [32]. Briefly, the nonhematopoietic,
nonendothelial stem cell fraction within human bone marrow which is crucial for niche maintenance has been
prospectively identified by expression of CXCL-12, (MCAM)/CD146 and expression of angiopoietin-1 [29], the
pericyte marker NG2 and PDGF-β [19]. Single CD45-/CD146+ cells expanded from human bone marrow establish
both hematopoietic tissue and bone organoids when transplanted ectopically [29], thus meeting expectations
for a true stem cell. In situ, CD146 expression is limited to ARCs within bone marrow sinusoid walls; these
cells are endothelial marker-negative (CD31/PECAM, CD133, VEFGR2, VE-cadherin) but express markers of
pericyte (α-SMA, PDGFR-β, calponins 1 & 3) and mural cell origin (NG2) [29,33]. Low-affinity nerve growth
factor receptor (CD271) is co-expressed with CD146 in perivascular locations, but absence of CD146 expression
(lin-/CD271+/CD45−/CD146−) allows in situ localization of another population of MSCs to endosteum [34].
Recently Chan et al. [35] reported that a PDPN+/CD146-/CD73+/CD164+ phenotypic profile identifies a human
skeletal stem cell (SSC) associated with growth plate rather than bone marrow, which is clonogenic in vitro and
produces bone, cartilage and hematopoietic stroma in vivo. These findings mark a departure from the usual picture
of bone marrow-derived MSC, in that adipogenic differentiation was not observed, and in contradiction to other
studies, the SSCs lack CD146 expression which locates MSC in perivascular (sinusoidal) sites [29,34]. It is thus
possible that the population identified by Chan et al. [35] represents a dedicated skeletal lineage independent of the
marrow-derived populations investigated to date.
MSCs in vitro
Bone marrow stromal cells, traditionally isolated from marrow via plastic adherence, form fibroblastic cell colonies
(colony-forming units-fibroblastic or CFU-Fs) [9] which form individual colonies when seeded at clonal den-
sity [36]. Expansion of single colonies reveals a mixture of multipotent, uncommitted cells and lineage-committed
progenitors [37–39]. However colony formation alone is insufficient to demonstrate stemness [16]. Multipotency and
self-renewal can only be demonstrated at the single cell level, since nonclonal populations may contain multiple
different committed progenitors which are selected for by the culture conditions, without the original population
ever containing a true stem cell [14].
A´lvarez-Viejo et al. [40] have highlighted the current absence of definitive identification criteria for MSC in fresh
bone marrow aspirate and other tissue sources. Markers such as Stro-1, SSEA-4, CD146, CD271, CD49f (α-6
integrin), MSCA-1 and 3G5 may be valuable alone or in combination for both isolation/enrichment of MSC
populations within cultures, and for selection of subsets with greater CFU-F and multipotency [40,41]. Many studies
have investigated the surface marker expression profile of cultured MSC, which have been reviewed extensively by
Mafi et al. [42], Calloni et al. [43], Kobolak et al. [44] and Samsonraj et al. [45].
Heterogeneity of MSCs
Any culture of stromal cells isolated from primary tissue will be a heterogeneous mixture: for example, bone
marrow aspirate contains a variety of hematopoietic cells, red blood cells and stromal cells including fat cells,
endothelial cells, fibroblastic cells and marrow stem/progenitor cells [46]. The initial isolation procedure for MSCs
frequently involves adherence to plastic. This characteristic, a key component of the ISCT’s identity criteria for
multipotent MSCs, separates nonadherent hematopoietic stem cells from the adherent fraction that is assumed to
be the ‘mesenchymal stem cell’ fraction. However fibroblasts have similar properties including plastic adherence [47]
and proliferation to >50 population doublings before senescence [48].
Donor variation is well recognized as a fundamental source of variability in MSC populations, including in
growth kinetics, and thus potential yields between donors and immunomodulatory capacity [49]. Donor age and
gender impact both yield and immune-suppressive functions [50]. Interdonor variability may also differ depending
on tissue source [51,52]. These variations will impact upon clinical and commercial development of MSC cell
therapies, especially autologous therapies, with respect to defining the characteristics critical for required clinical
effects.
Populations of MSC in culture will contain different proportions of true stem cells and differentiation-committed
progenitors. Individual cells within a culture proliferate, differentiate and senesce at different rates, such that it
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cannot be accurate to represent a culture of bone marrow stromal cells as a homogeneous population of MSCs [16].
Cultures seeded at nonclonal densities will produce mixed populations of adherent cells, some of which arise from
clonogenic cells but others from nonclonogenic cells, which will be limited in their growth potential. Cultures re-
established from single clones contain clonogenic self-renewing stem cells but these cultures become heterogeneous,
reflecting the fundamental heterogeneity of the starting material [29,37].
Single colony-derived bone marrow stromal cells vary in their potential to induce bone formation in vivo,
compared with polyclonal populations, which invariably form bone upon transplantation [53]. In vitro differentiation
potential is likewise variable between individual clones: in one study >20% of clonally-derived human stromal
cell strains showed tri-lineage differentiation potential to all three osteogenic, chondrogenic and adipogenic (OAC)
lineages in vitro, with the majority being osteogenic-chondrogenic (OC) bi-potent clones [54]. This study reported
absence of clones with OA or CA bipotential, and chondrogenic-only, adipogenic-only and nullipotent clones.
Similar work produced all possible combinations of tri-, bi-, uni- and nulli-potent clones [39]; these differences were
ascribed to experimental and culturing differences, which in itself highlights the difficulty of comparing outcomes
across studies. These studies indicate a hierarchical specification resulting in heterogeneous functionality within
MSC populations [55].
Populations expanded from single colonies of human bone marrow stromal cells from a single donor show wide
variation in differentiation potential following in vivo transplantation: 67% bone-forming but only 12.5% forming
bone and hematopoietic tissue, and around 20% forming only fibrous tissue [56]. Multi-potency appears related to
other stem-like properties: clones showing differentiation potential to all three lineages are likely to be those with
higher colony-forming capacity, faster doubling times and slower progression to senescence in vitro than those with
uni- or bi-potency [57]. These studies all support the prevailing view that multipotent stem cells represent only
a small fraction of the total nucleated bone marrow stromal cell population, and that clonogenicity alone is not
indicative of stemness. Colony-forming assays in isolation overestimate the proportion of stem cells in a sample
of bone marrow or other material, since committed osteoprogenitors are clonogenic but uni-potent [58]. Ex vivo
markers of osteoblastic phenotype (e.g., ALP) were not predictive of the in vivo bone-forming capacity. Therefore,
it is of a great interest to define ex vivo molecular markers that are better at predicting the in vivo bone-formation
capacity of BMSCs.
The preceding studies used nonimmortalized bone marrow stromal cells in extended culture, which invariably
results in loss of differentiation potential [54]. Immortalization of MSCs by retroviral transduction with human
telomerase reverse transcriptase (hTERT) complementary DNA bypasses culture-induced senescence and main-
tains proliferative and multi-lineage differentiation capacity over >260 population doublings [59]. Availability of
practically inexhaustible stocks of consistent MSCs allows for detailed analyses of the potential of populations
derived from single cells. MSCs from a single donor, immortalised via lentiviral transduction with hTERT, pro-
duce a range of clones demonstrating both multi-potent differentiation capability and nullipotency [60]. Global
gene expression arrays identified distinct phenotypes, with multipotent clones showing upregulation of a range of
vascular development and growth genes, and an inflammatory gene profile including IFN-γ, TNF-α and IL-7 in
the poorly differentiating clones. The inflammatory clones expressed CD317, and selection by CD317 identified
a small fraction (1–3%) with high IL-7 expression within primary stromal cell culture, suggesting that these clones
represent a subset within primary stromal cell populations. Similarly Elsafadi et al. [61] reported on two clones from
hTERT-MSC that displayed fundamentally different phenotypes: one expressed high levels of osteogenic markers
(alkaline phosphatase and CD146), bone and skeletal muscle-related genes, and differentiated to bone, fat and
cartilage in vitro; the other expressed increased immunomodulatory and immune defence genes and showed greatly
reduced tri-lineage differentiation potential. Of note, clones from both studies all expressed a range of ‘expected’
MSC markers including CD29, CD44, CD63, CD73, CD90, CD105 and CD166 despite such large differences
in differentiation potential.
The use of immortalization to facilitate reproducible studies on consistent cells is a valuable research tool that
allows exploration of the inherent heterogeneity of MSCs but such cell lines may not reflect the natural organization
or characteristics of bone marrow stromal cells either in vivo or in short-term nontransformed culture, the latter
being more likely to be used for production of cell therapy medicines. The preceding studies illustrate the difficulty
in producing a consistent population of cells for therapeutic use. Even with tissue from a single donor, controlled
culture conditions and expansion from a single cell, each clone produces a distinct population with widely different
morphology, growth kinetics, gene expression profile and functional protein expression.
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Figure 2. Spectrum of approaches to mesenchymal stem cells in regenerative medicine.
Literature concerning use of mesenchymal stem cells in clinical applications appears to represent a spectrum of
opinions: at one end of the spectrum strong support for exploring a vast range of therapeutic indications using cells
from a range of tissues, and at the other a more cautious, strictly evidentiary approach that emphasizes the
importance of detailed empirical support for all likely mechanisms and avoidance of any assumptions whatsoever
regarding anticipation of clinical beneit. The rate of clinical update may be supported by a more exploratory
approach based on assumptions concerning ‘generic’ mesenchymal stem cell properties.
Issues for regenerative medicine
MSC in regenerative medicine: a range of perceptions
Reporting of the isolation of stromal cells possessing multilineage differentiation capacity from a wide range of
tissues including adipose, placenta, umbilical cord (UC) and dental pulp has led to a situation in which attributes
observed in vivo from bone marrow-derived MSC have been extrapolated to make assumptions about cultured
cells. These assumptions have apparently been the basis of a rationale for clinical application of expanded MSC in
a variety of therapeutic indications. These applications reflect expectations based on the current understanding of
the behavior of MSCs in vitro, and suggest an assumption that properties exhibited in a culture environment will
necessarily be maintained upon administration to a patient.
The apparent acceptance that all tissue sources contain stem cell populations comparable to those seen in bone
marrow stroma has led to a noticeable divide in published views of the use of MSC in clinical development
(Figure 2): at one end of the spectrum there is strong support for exploring a vast range of therapeutic indications
using cells from a range of tissues, and at the other a more cautious, strictly evidentiary approach that emphasises the
importance of detailed empirical support for all likely mechanisms and avoidance of any assumptions whatsoever
regarding anticipation of clinical benefit. Somewhere in the middle, the ever-increasing pool of clinical reports may
encourage exploratory use based on the lack of significant adverse events being reported, although in isolation this
should not be considered a reliable indicator of patient safety.
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The literature clearly highlights the extensive variation among populations of MSCs whether arising from tissue
source, culture conditions or population doublings, and one of the most important aspects with relevance to
regenerative medicine is the extent to which a population of MSCs derived from a single donation/tissue can
vary. It will be important, and also challenging, to elucidate the profiles of subsets most promising for different
indications, which implies identification of subsets with relevant gene/protein expression for the intended function
and ability to isolate these subsets based on accessible epitopes.
Differences between tissue sources
The ability to culture such colonies of stromal cells from many different tissues has contributed to the expectation
that multiple sources contain cell populations with analogous properties to bone marrow-derived stem cells [19,20].
However differences between tissue sources are apparent: although absence of CD34 expression is stipulated in the
ISCT minimal identity criteria for cultured MSCs [21], CD34 expression is recommended for fresh MSCs within
stromal vascular fraction and is noted as an ‘unstable primary marker of cultured adipose-derived stromal/stem
cells’ [62]. Although, presumably because of the nonspecificity of the ISCT marker panel, expanded stromal cells from
many tissues meet the minimal criteria for MSC identity, differences in gene expression and differentiation potential
between tissue sources are reported [52,63–65]. Stromal cells from non-marrow sources including adipose, UC and
menstrual blood, have been shown to express different surface marker profiles [63,66], whereas synovial membrane-
derived stromal cells appear phenotypically closer to bone marrow-derived MSCs [67]. Perinatal tissues represent an
accessible source of cells for regenerative medicine without the necessity for invasive harvesting procedures. Whilst
generally reflecting the expected MSC surface markers, functional differences between sources are apparent. MSCs
from UC blood show considerable heterogeneity in terms of expansion and immunomodulatory capacity [68].
There are reports that UC-derived MSCs (UC-MSCs) have greater expansion capacity, greater osteogenic and
adipogenic potential, and higher CD146 expression than bone marrow MSCs [63,69]. MSCs from different layers
of the placenta show variation in proliferation and differentiation capacity [70], and MSCs from amnion also show
variable differentiation potential and high inter-donor variability compared with UC-MSCs [52].
The developmental origins of MSC may include neural crest [71]. Further heterogeneity of stromal cell populations
from bone marrow, adipose and skin is evidenced by the presence of neural crest-derived stem cells [72,73] within
the population expressing expected MSC markers CD73, CD90 and CD105.
The explosive growth of the MSC cell therapy industry has been based, in part, on the expectation of tissue/source
equivalence, with 26% of current EU clinical trials using adipose-derived MSCs, and 30% not stating the tissue
origin in the publicly accessible trial details on the EU clinical trial register EudraCT (Figure 3). Although tissue
source will have been disclosed to the regulatory authorities, it is interesting that the trial sponsors did not apparently
consider it to be a significant detail in the main application forms for the clinical trial authorization.
The potency assay: linking identity & variability to regulatory expectations
Medicinal products, including cell therapies, are regulated on the basis of their intended therapeutic indication.
That is, the applicant for a clinical trial or marketing authorization has to define what condition is to be treated
or prevented, or what clinical effect the medicinal product is intended to achieve. Early in product development,
there may be only prior literature, or hints from primary research, to guide identification of mechanisms that
could deliver potentially useful clinical effects. These clues must ultimately be crystallized into a package of data
that identifies the active moiety (chemical substance, biological molecule or cellular component) and demonstrates
its safety and effectiveness in the proposed clinical indication. Elucidation of relevant mechanisms of action is
thus a key aspect of development of cellular therapies. While it may be almost impossible to identify all possible
mechanisms, an understanding of the major properties likely to result in the intended biological activity is essential.
For the medicinal product to be licensed, allowing it to become accessible to patients on a routine basis, regulatory
requirements must be met. A critical aspect of development of all biological medicines is the requirement for a
potency assay: one or more assays capable of confirming that the batch of product meets established specifications
for relevant biological activity when compared against a reference standard or performance criterion, thus ensuring
consistency of production [74,75]. Potency assays are expected to be correlated with clinical performance, allowing
confirmation that each batch has the same biological functionality as those tested in clinical trials. Since the
potency assay must relate to a biological property relevant for the intended indication, quantitative measures
based on understanding of the specific mechanisms of action are required. The challenges of identifying relevant
properties for cell therapies are significant because, unlike conventional medicinal products, the administered cells
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Figure 3. Tissue sources in EU mesenchymal stromal cells clinical trials.
From the 98 clinical trials involving mesenchymal stromal cell as the investigational medicinal product currently
registered on EudraCT, 32 (33%) stated the source of mesenchymal stromal cell as BM, 25 (26%) utilized AD and 29
(30%) did not specify the NS in the primary record or the Competent Authority application form. Skin, UC, W and
placenta were also mentioned as source tissues.
Source: EudraCT www.clinicaltrialsregister.eu (Accessed 3 November 2018).
AD: Adipose tissue; BM: Bone marrow; NS: Source tissue; UC: Umbilical cord; WJ: Wharton’s jelly.
Table 2. Properties of mesenchymal stromal cells with potential for potency assay development.
Indication Properties relevant to potency assay development Ref.
Multiple organ dysfunction syndrome IL-10 release [82]
Graft-vs-host disease TNF-R1 expression [83]
Multiple immune/inlammatory conditions T-cell proliferation suppression [49]
CD4+ T-cell proliferation suppression [84]
TNF- inhibition [85]
Corneal damage from chemical insult TNF- stimulated gene/protein 6 (TSG-6) expression [86]
Acute myocardial infarction In vitro tubule formation (CXCL5, IL-8, VEGF expression) [87]
Cartilage repair Receptor tyrosine kinase-like orphan receptor 2 (ROR2) expression [88]
are likely to interact in a complex and potentially unpredictable manner with the recipient’s tissues and physiological
mechanisms.
Consideration of the requirement for a potency assay, or more likely a combination of complementary assays,
highlights the necessity of understanding the broad mechanisms of action of the product. Immunomodulatory
properties of MSC have been studied extensively in in vitro and in vivo assays [76–78]. Although often characterised
by suppression of T-cell proliferation induced by mixed lymphocyte reactions or other pro-inflammatory stimuli,
the specific mechanisms by which MSCs achieve these effects are complex and multimodal [79]. Recent ISCT
publications discussed approaches to developing potency assays in immunomodulatory applications [80,81]. Table 2
illustrates a range of properties of MSCs which may be suitable for development as potential potency assays for
mesenchymal stem/stromal cell therapies.
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For cellular therapies and in particular those intended for tissue repair/regeneration, there are likely to be a range
of mechanisms involving secretion of trophic support molecules [26,89–91]. The clinical exploration of MSCs for
neurological conditions including multiple sclerosis and stroke has been justified based on such mechanisms [92–
94]. In situ differentiation into site-specific tissue for repair of tissues/organs, once a cornerstone of the MSC
treatment paradigm, is increasingly rejected as evidence of lack of engraftment and persistence following intravenous
or local injection accumulates, pointing to paracrine effects rather than replacement with differentiated tissue
de novo for nonskeletal indications [89,95,96]. Inherent donor-related variability in immunosuppressive activity
may account in part for inconsistent clinical trial outcomes [97]. The MSC secretome and thus cells’ paracrine
activity is profoundly impacted by microenvironment [98]. Immunomodulatory activity in particular requires a
pro-inflammatory environment to prime MSCs [99] thus preconditioning of MSCs with cytokines may increase
expression of potentially therapeutic molecules [100,101]. Priming MSCs with Toll-like receptor (TLR)-3 agonists
induces an immunosuppressive phenotype [102]. Aside from paracrine mechanisms of action, priming of different
TLR family members may impact upon differentiation potential [103,104], although the therapeutic value of this
observation is unclear given that site-specific differentiation of MSCs in bone and cartilage injury has yet to be
definitively confirmed in clinical trials.
For many regenerative applications, stem properties (self-renewal, multipotency) may therefore not be relevant
at all. In this vein, the concept of MSC as ‘medicinal signaling cells’ arises [25,27]. Production and delivery of
therapeutic molecules via MSC-derived exosomes, intracellular nanoparticles involved in intercellular signaling and
release of lipids, proteins and nucleic acids, is mooted as a possible alternative to the use of MSC themselves as the
therapeutic agent [105]. The potential of MSC-derived exosomes is under exploration in numerous areas including
myocardial infarction [106], osteoarthritis [107] fracture healing [108] and neurodegenerative disease [109]. Composition
and activity varies in exosomes from different tissues [110,111]. Exosome-based therapy may avoid some potential
risks of cell administration, but challenges around mechanism of action, production at scale and consistency will
need to be addressed in the same way as for MSC-based therapies [112].
With a vast range of potential molecules, pathways, networks and interactions that could contribute to clinical
efficacy of a MSC-based cell therapy, assessment of the means by which it achieves its effects becomes incredibly
challenging. Fortunately regulators in the EU and the US do not expect fully developed potency assays as a condition
of entry into clinical trials in human subjects; however a rationale to underpin the choice of indication and some
evidence that the cell-based therapy can deliver relevant effects will be required before human trials begin, usually
in the form of nonclinical pharmacology studies. Given the complexity of the potency issue, it is inevitable that
there is a link back to identity of the cell population being developed. The identity profile needs to be defined
during development, such that the impact of materials used for production, the control and consistency of processes
employed can be assessed to ensure product of a consistent and relevant biological functionality can be generated.
This in turn supports the production of consistent batches of cell product for the intended clinical effect: all are
integrally linked (Figure 4). Thus understanding of the identity of the population is critical, and investigation
of the relevant phenotypic and functional attributes is a fundamental aspect of cell therapy development. Clearly
the heterogeneity associated with MSC populations creates additional complexity in terms of the conventional
requirement to define the ‘drug substance’.
A more defined phenotype capable of predicting a required biological function in vivo should facilitate production
and clinical evaluation of cell therapies [113]. However a key challenge in therapeutic application of MSCs appears
to be that the surface markers commonly associated with in vitro functionality are not necessarily related to the
corresponding activity in vivo. Global gene expression analysis may allow the elucidation of relationships between
phenotype and function by highlighting possible relationships that are not immediately apparent [56]. However, large
differences in expression (>tenfold) can be seen in cell strains with the same differentiation potential, underlining
the difficulties in correlating gene expression with in vivo function.
Impact of heterogeneity on cell therapy manufacture
MSCs are a major candidate for a wide range of potential therapeutic applications. Although the actual cell numbers
required to treat an individual patient may vary with indication, it is certain that the overall numbers required
to produce commercially and clinically viable products will necessitate effective expansion strategies. However
the expansion of MSCs in adherent culture is known to result in slowing and eventual loss of proliferation [114]
and loss of multi-lineage differentiation potential [115,116]. Possible strategies for countering these effects may
include culture in hypoxic conditions, which affects MSC proliferation, differentiation capacity, migration and
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Tissue source, anatomical location, donor
variables, inherent biological variability of cells
Consistency and suitability of materials and
control of manufacturing process essential for
consistent cell therapy manufacture
Identity of final cell population driven by
starting material consistency, biological
consequences of manufacturing steps and
measured via potency assay. Clinical effect
depends upon administration of consistent
product
Potency assay(s) assure consistent biological
effect as measured. Intention to assure each
batch of product will deliver clinical effect as
seen in clinical trials
Clinical effect relies on minimisation of
variability throughout manufacturing process
1 Starting material identity
2 Materials/process control
3 Cell product identity4 Potency
5 Clinical effect
4
5
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Figure 4. Identity as an integral part of cell therapy manufacture.
Each aspect of the manufacture of consistent and effective cell therapies is linked: heterogeneity of the starting material (tissue/cell
source) is a fundamental source of variability which impacts upon the overall ability of the process to deliver an effective product with
consistent relevant biological functionality equivalent to that assessed in clinical trials.
metabolism [117]. Hypoxic conditions can result in lower intracellular concentrations of reactive oxygen species
(ROS), which are implicated in multiple adverse mechanisms during cell expansion (e.g., telomere shortening,
chromosomal damage) [118].
The current challenges in identification of MSCs with true stem potential means that the expanded cells
administered to a patient may comprise a heterogeneous population identified only by plastic adherence and
the expression of a few nonspecific surface markers. This is of particular importance in early clinical trials, in
which the supporting functional evidence generated in small animal models may have been achieved with much
smaller cell numbers produced via fewer population doublings: a less expanded population of MSCs will likely
represent a different population with differing proliferation and differentiation capacity. Differences in administered
populations may result in failure and rejection of promising therapies when results in animal studies are not replicated
in early clinical trials. Although difficult to assess this directly, it is certainly the case that many successful studies in
animals do not translate/have not yet translated to positive results in the clinic. Whilst regulators do not currently
require cell-based products to be absolutely pure, and in any case there would be significant challenges in defining
what this means in practice, certain regenerative medicine applications may benefit from use of a clonal population
rather than a heterogeneous material expanded from multiple primary cells [119].
Studies of culture methods intended to increase yields of MSCs for clinical use tend to quantify output by char-
acterizing the expanded populations in terms of phenotype, plus occasionally morphology and immunosuppressive
activity, for example, Gottipamula et al. [120], Haack-Sorensen et al. [121]. Similarly efforts to create biobanks of
MSC have been assessed on the basis of ISCT or similar criteria alone [122]. These are entirely reasonable approaches
for evaluation of a manufacturing process, but for the reasons already discussed, these criteria do not adequately
identify the stem/progenitor content of the population and may thus tend to over-estimate the relevance of the
output cells for some clinical applications.
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Box 1. European Union.
• Regulation (EC) No 1394/2007 Article 2.1 (b) ‘Tissue engineered product’ means a product that:
– contains or consists of engineered cells or tissues
• 2.1 (c) Cells or tissues shall be considered ‘engineered’ if they fulill at least one of the following conditions:
– the cells or tissues have been subject to substantial manipulation, so that biological characteristics, physiological
functions or structural properties relevant for the intended regeneration, repair or replacement are achieved.
The manipulations listed in Annex I, in particular, shall not be considered as substantial manipulations
– the cells or tissues are not intended to be used for the same essential function or functions in the recipient as in
the donor
• Directive 2001/83/EC Annex Part IV 2.2.(a): Somatic cell therapy medicinal product means a biological medicinal
product which has the following characteristics: (a) contains or consists of cells or tissues that have been subject
to substantial manipulation so that biological characteristics, physiological functions or structural properties
relevant for the intended clinical use have been altered, or of cells or tissues that are not intended to be used for
the same essential function(s) in the recipient and the donor;
USA
• 21 CFR 1271.10
• a) An HCT/P (human cells, tissues and cellular and tissue-based product) is regulated solely under section 361 of
the PHS Act and the regulations in this part if it meets all of the following criteria:
• . . . (2) The HCT/P is intended for homologous use only, as relected by the labeling, advertising, or other
indications of the manufacturer’s objective intent;
Future perspective
Different populations showing multi-potentiality in vitro can be isolated from many stromal tissues. The presence
of true stem cells has been demonstrated in bone marrow [29] and in fetal and adult bone [35], but ‘stemness’ appears
to be assumed in other tissue sources. Identification of cells as stem or multipotent stromal is a crucial distinction
from the biological perspective and it should be a priority to define clearly the terms and assumptions in this regard
in study publications. But how important is this for regulatory aspects in relation to regenerative medicine? If a
population only contains a small proportion of true stem cells as defined in specifications, is this important? It is
clear that the cultured MSCs embraced by the regenerative medicine community are not equivalent in all respects
to the native population residing in the perivascular/sinusoidal hematopoietic niche. They do not have, indeed
are not required to have, the same functions, in that they are not intended to support the HSC niche. Similarly,
the production of new bone in natural skeletal replenishment or repair, orchestrated by a specific and controlled
sequence of physiological signals, is not likely to be recapitulated during administration of ex vivo expanded MSCs.
Regulatory authorities recognize the distinction between the native functions of cells and their potential uses in
medicinal products. The cell therapy regulations in both the EU and the US make a distinction between cells
intended to perform the same intended function as native cells and those for which the intended clinical purpose of
the cells is different to that which the cells would normally perform in the body, with this so-called ‘nonhomologous
use’ being regulated by medicines/biologics legislation (Box 1).
The rigor applied in primary research to further elucidating the locations, properties and functions of individual
sets of bone marrow stem and stromal cells, and stromal cells from other tissues, is essential to help inform selection of
appropriate populations for regenerative medicine applications. There is abundant evidence that stromal cells from
different tissues exhibit differences in marker profiles, gene expression patterns and propensity to differentiate into
particular cell types. Inherent heterogeneity of cell populations makes characterization challenging, but developers
of regenerative medicines should take into account the basic biological attributes of their chosen cell type, perhaps
considering the optimum tissue source and desired functionality based on a combination of fundamental biology
and understanding of the impact of processing conditions during cell expansion.
Developers of MSC-based therapies need to be cautious in their assumptions about the identity and relevant
mechanisms of action attributed to their cell population. The expression of a range of nonspecific surface antigen
markers is to be expected for MSCs; in order to be relevant for regulatory identity requirements, developers
should seek to identify combinations of markers more specific to the cell population produced in their particular
manufacturing process. The ability of a specific cell population to deliver particular biological functionality must
be explored in the context of the intended indication, and not by application of a generic in vitro differentiation
assay that may have little or no specific relevance to that indication.
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We should be mindful, however, not to paralyze the field of regenerative medicine with ambitious goals that may
hinder valuable clinical progress: a balance between detailed understanding of native biology and practical analysis
of the cell population under development is essential. It is important to emphasize that different stakeholders will
have different interests and objectives: research scientists seek elucidation of the biology of cells within their native
environment; regulators require that the specific cell population, in other words, the ‘drug substance’ for clinical
application is characterized, and the cell therapy community could benefit from a standard set of criteria that may
be helpful in providing a baseline for comparison of results. Does it matter what we call these cells when each
clinical trial application requires individual identity, cellular composition and relevant potency criteria for the cells
and process under consideration for a specific indication? From a purely regulatory perspective, probably not, but in
order to allow for meaningful comparisons during research we should seek clarity of terminology and descriptions,
avoiding universal attribution of properties elucidated under specific circumstances.
As the clinical use of MSCs increases, it would be of value to the research community to share key data.
For example, publicly accessible databases such as the Stemformatics stem cell project [123] allow submission and
sharing of gene expression and pathway data, enabling researchers to compare their data to others. Single cell RNA
sequencing can characterise differences in the differentiation and immunomodulatory potential of MSCs at the
single cell level [124]. Developers of MSC-based products may benefit from more comprehensive characterization
data as the number of batches of cells increases: compilation and analysis of RNAseq data for cells used in clinical
trials may eventually yield valuable insights in terms of the clinical consequences of heterogeneity of MSCs.
Executive summary
Background
• Variation is a fundamental concept in biology.
• Heterogeneity arises in clonal cell populations.
• Potential challenges for the regulatory framework because of mesenchymal stromal cell (MSC) heterogeneity.
• Clinical trials in the EU are exploring the use of MSCs in a wide range of different therapeutic applications.
MSC nomenclature
• Stem or stromal? Are the two terms conlated in the MSC literature?
• Deinitions and additional ‘MSC’ acronyms, and the use of ’standard’ identiication criteria for cultured MSCs.
MSCs in vivo
• Brief history of the identiication and functions of MSCs within the hematopoietic niche.
• Phenotypic identiication of a putative human skeletal stem cell.
MSCs in vitro
• Identiication of colony-forming units – ibroblastic within bone marrow stroma.
• Isolation and enrichment by cell surface markers.
Heterogeneity of MSCs
• Impact of donor age, gender and tissue source.
• Colonies form a heterogeneous mix of cells with varying self-renewal capacity and multipotentiality, and not a
population of ‘stem’ cells.
• Cultures expanded from single colonies demonstrate extensive heterogeneity both within and between cultures.
• Single clones from immortalized MSC cell lines show profoundly different gene expression proiles and
differentiation capacity.
Issues for regenerative medicine
• Perceptions of MSC: a spectrum of approaches to their use in regenerative medicine.
• Equivalence of tissue sources.
• The potency assay – linking identity and variability to regulatory expectations.
• Impact of heterogeneity on cell therapy product manufacture.
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